VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases.
Location: United States, California, Mountain View
Total raised: $33.6M
Founded date: 1991
Investors 5
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Galen Part... | galen.com |
| - | Aisling Ca... | aislingcap... |
| - | Valence Li... | valencefun... |
| - | Frazier Li... | frazierls.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.11.2006 | - | $33.6M | - |
Mentions in press and media 5
| Date | Title | Description |
| 05.03.2024 | Choosing the right weight management medication to best suit your health goals | (BPT) - Struggling with weight loss is a problem everyone is familiar with – either they themselves or someone close to them has faced challenges in maintaining a healthy weight. Obesity is a disorder involving excessive body fat that incre... |
| 13.10.2022 | A Colorado biotech ends clinical work to focus on marketing ADHD drug, consumer health products | A biopharma that markets an ADHD medication, and sells a portfolio of over-the-counter consumer health products on Amazon and elsewhere, has decided to scrap all work on clinical-stage assets. The Englewood, CO-based biot... |
| 20.07.2022 | FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17 | CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in... |
| 14.12.2010 | Vivus Submits Document to FDA | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Vivus (NASDAQ: VVUS), the Mountain View, CA-based based obesity drug developer, said today it has submitted a briefing document to the FDA to answer questions the agency raise... |
| 21.11.2006 | Vivus, an obesity and sexual health drug company, gets $33.6M | Vivus, a publicly traded Mountain View drug developer focused on obesity and sexual health, received $33.6 million in private equity financing, after the company announced deepening losses. Caxton Advantage Life Sciences Fund led the financ... |